Vermillion Incorporated has one goal: to develop and produce diagnostic tests that help physicians diagnose, select appropriate treatments and improve outcomes for patients. Vermillion develops clinical protein biomarker diagnostic products and services for use in the fields of oncology, hematology, cardiology, and women’s health. The company has several working relationships with academic and research institutes for the discovery and development of new products.

Vermillion applies a three-step approach when looking for a new solution to an existing problem. They first acquire information about the disease; this is done by applying a multi-biomarker approach to identify associations between genes, proteins and diseases that translate into meaningful information about disease states. Once this information is acquired Vermillion conducts multi-institutional studies, including clinically relevant controls, and partitioning of training from validation data to find the results. Finally Vermillion then uses this information to create and commercialize high-value diagnostic tests intended to help physicians perform quicker and more accurate tests.

Since 2005 Vermillion Incorporated has had an important strategic alliance with Quest Diagnostics. The partnership helps with the commercialization of protein biomarker diagnostic tests. Quest’s partnership is also focused on the development and commercialization of three diagnostic tests chosen from Vermillion’s pipeline. To date, Quest has chosen two of Vermillion’s tests for development: the ovarian tumor triage (OTT) test and the peripheral artery disease (PAD) test.

Let us hear your thoughts: Vermillion Inc. Message Board